Contrast-enhanced Ultrasound to Predict Outcomes of Radioembolization Therapy in Hepatocellular Carcinoma
Monday, April 8, 2024
4:43pm – 4:53pm
Location: 406
Authors: Lauren Delaney, Thomas Jefferson University Corinne Wessner, Thomas Jefferson University Sriharsha Gummadi, University of Pennsylvania Priscilla Machado, Thomas Jefferson University Flemming Forsberg, Thomas Jefferson University Andrej Lyshchik, TJUH PATRICK OKANE, Thomas Jefferson University Hospital Allison Tan, Thomas Jefferson Hospitals Colette Shaw, radiology associates of atlanta Kevin Anton, Thomas Jefferson University John Eisenbrey, Thomas Jefferson University
Treatment response of hepatocellular carcinoma (HCC) to radioembolization therapy (RT) is notoriously challenging, and can take up to 6 months before a conclusive diagnosis. The purpose of this study was to determine if quantitative contrast-enhanced ultrasound (CEUS) can predict long term response of HCC to RT. After evaluating CEUS exams from 33 patients receiving RT treatment, we found that CEUS appears to provide an earlier indicator of RT response at 1-2 weeks compared to the current 2-6 month post-treatment MRI.